Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

851
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
851
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

3.4K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and Biological Evaluation of 4‑Bromo-<i>N,N-</i>dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development.

ACS omega·2026
Same author

ASO Author Reflections: Atypical Breast Lesions on Core Needle Biopsy: Defining a Low-Risk Population to Guide Selective Surgical Excision.

Annals of surgical oncology·2026
Same author

Risk Stratification of Atypical Breast Lesions Diagnosed on Core Needle Biopsy: Toward Selective Surgical Excision.

Annals of surgical oncology·2026
Same author

Development and validation of a UPLC-MS/MS method for real-time neuropharmacokinetic monitoring of iboga alkaloids in rat brain.

Journal of pharmaceutical and biomedical analysis·2026
Same author

α-Synuclein and γ-Tubulin Cooperatively Regulate Activity-Evoked Presynaptic Microtubule Nucleation to Gate Dopamine Release.

bioRxiv : the preprint server for biology·2026
Same author

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-<i>N</i>-methyl-<i>N</i>-isopropyltryptamine and Related Analogs.

ACS chemical neuroscience·2026

Related Experiment Video

Updated: Jan 7, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.7K

Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses.

Christopher Hwu1, Václav Havel1, Xavier Westergaard2,3

  • 1Department of Chemistry, Columbia University, New York, New York 10027, United States.

Journal of the American Chemical Society
|December 26, 2025
PubMed
Summary

Ibogaine and its metabolite noribogaine inhibit vesicular monoamine transporter 2 (VMAT2) and serotonin transporter (SERT). This dual action, termed "Synaptic Reuptake Inhibitors" (SynRIs), explains ibogaine

More Related Videos

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.5K

Related Experiment Videos

Last Updated: Jan 7, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.7K
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.5K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Ibogaine, derived from the iboga tree, shows therapeutic potential for various neurological and psychiatric conditions.
  • Understanding its mechanism of action involves examining its effects on monoamine neurotransmitter transporters.

Purpose of the Study:

  • To systematically investigate the effects of ibogaine, noribogaine, and iboga analogs on monoamine transporters.
  • To elucidate the neurochemical mechanisms underlying ibogaine's therapeutic effects.

Main Methods:

  • Cell-based fluorometry assays to assess VMAT2 transport function.
  • Two-photon microscopy to visualize transporter activity in mouse brain.
  • Uptake and release assays using radiolabeled serotonin in isolated brain synaptic vesicles.
  • Inhibition assays for plasma membrane monoamine transporters (MATs), including SERT and OCT2.

Main Results:

  • Ibogaine and noribogaine inhibit VMAT2 with submicromolar potency.
  • Noribogaine was found to induce partial serotonin release from synaptic vesicles.
  • Iboga compounds inhibit SERT and OCT2, with some analogs showing dual VMAT2 and SERT inhibition.
  • These dual inhibitors were termed "Synaptic Reuptake Inhibitors" (SynRIs).

Conclusions:

  • The SynRI profile provides a model for ibogaine's neurochemical effects and therapeutic potential.
  • This updated understanding of iboga pharmacology, termed "matrix pharmacology," helps explain why ibogaine does not induce catalepsy unlike other VMAT2 inhibitors.